英夫力西治疗炎症性肠病与肠道菌群改变的相关性研究

目的探讨使用英夫力西(IFX)治疗炎症性肠病与肠道菌群改变的关系。方法收集104例炎症性肠病患者,其中溃疡性结肠炎(UC)52例,克罗恩病(CD)52例,使用英夫力西治疗前后测定肠道菌群数量。另取30例健康志愿者新鲜粪便,定量培养进行菌群分析,同时测定三组C反应蛋白、血沉两项数据结果,分析其与肠道细菌组成变化的相关性。结果治疗后,UC组酵母菌(1.09±0.17)、肠球菌(5.01±0.36)和消化球菌(3.99±0.23)的数量显著下降,乳酸杆菌(7.95±0.69)的数量显著上升(P<0.01);CD组酵母菌(1.06±0.19)、肠球菌(4.91±0.37)和消化球菌(3.90±0.19)的数量显著下降,乳酸杆菌(8.07±0.76)的数量显著上升(P<0.01)。治疗后,UC组CRP(10.33±4.64)、ESR(9.10±4.11)水平降低(P<0.01);CD组CRP(7.31±4.68)、ESR(9.27±3.13)水平降低(P<0.01)。结论使用英夫力西治疗炎症性肠病患者后,酵母菌、肠球菌和消化球菌数量显著降低,乳酸杆菌数量显著增加,恢复到正常水平,炎症指标CRP和ESR下降,临床症状得到有效缓解。

Correlation between changes of intestinal flora and infliximab as therapy in patients with inflammatory bowel disease

Objective To investigate the correlation between infliximab treatment for inflammatory bowel disease (IBD) with the changes in intestinal flora.Methods We collected 104 IBD patients (including 52 cases with ulcerative colitis and 52 cases with Crohn's disease) and 30 healthy volunteers.The intestinal flora was analyzed.The levels of CRP and ESR were detected to assess the correlation between intestinal flora and inflammatory markers.Results After treatment, the number of Saccharomyces (1.09±0.17),Enterrococcus (5.01±0.36) and Peptococcus (3.99±0.23) decreased significantly, while that of Lactobacillus (7.95±0.69) increased markedly in patients with UC (P<0.01);the number of Saccharomyces (1.06±0.19),Enterrococcus (4.91±0.37) and Peptococcus(3.90±0.19) decreased significantly,while that of Lactobacillus(8.07±0.76) increased markedly in patients with CD (P<0.01).The levels of CRP and ESR decreased significantly in UC patients(10.33±4.64,9.10±4.11, P<0.01) and CD patients (7.31±4.68, 9.27±3.13, P<0.01).Conclusion Infliximab therapy can decrease the number of Saccharomyces,Enterrococcus and Peptococcus,while increase the number of Lactobacillus in patients with IBD,and decreased the levels of CRP and ESR,thus relieving the clinical symptoms effectively.